High-grade gliomas are the most aggressive primary brain tumors in adults, carrying a prognosis that remains poor despite decades of research. The most common and most lethal subtype, glioblastoma, has a median survival of roughly 15 months with standard treatment. Yet the landscape has shifted meaningfully since 2021, when the World Health Organization overhauled how these tumors are classified, making molecular features as important as what the tumor looks like under a microscope. That change has opened the door to more precise therapies and more honest conversations about what a given diagnosis actually means for a given patient.
What Counts as a High-Grade Glioma
Gliomas are tumors that arise from the supportive glial cells of the brain and spinal cord. They are graded on a scale of 1 through 4, with grades 3 and 4 considered “high grade.” Grade 3 tumors (anaplastic gliomas) grow faster than their low-grade counterparts and tend to recur aggressively. Grade 4 tumors, which include glioblastoma, are the fastest-growing and most infiltrative.
The 2021 WHO classification fundamentally changed how these diagnoses work. Previously, a pathologist’s visual assessment of the tissue drove the grade. Now, molecular characteristics are required for a complete diagnosis. Diffuse gliomas are separated into adult-type and pediatric-type categories for the first time, and specific genetic markers can override what the tissue looks like under a microscope.1Oxford Academic. Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline This means two tumors that look identical on a slide may receive different diagnoses and carry very different prognoses based on their molecular profiles.
The Molecular Markers That Shape Prognosis
Two molecular features dominate conversations about high-grade glioma outcomes: IDH mutation status and MGMT promoter methylation. Understanding what they mean in practical terms matters for anyone navigating a diagnosis.
IDH Mutations
IDH (isocitrate dehydrogenase) is an enzyme involved in cellular metabolism. When the gene encoding it carries a mutation, gliomas tend to behave less aggressively. In the pre-2021 classification, some glioblastomas carried IDH mutations. Under the current system, an IDH-mutant grade 4 diffuse glioma is classified differently from an IDH-wildtype glioblastoma, reflecting the fact that these are biologically distinct diseases with different expected trajectories.
The survival gap is substantial. In patients with secondary high-grade gliomas (those that evolved from a lower-grade tumor), those with IDH mutations had a median survival of about four years after the tumor became aggressive, compared with roughly 1.2 years for patients whose tumors lacked the mutation.2PubMed. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas IDH status, along with how much tumor can be surgically removed and the patient’s age, consistently ranks among the strongest predictors of how long someone will survive.3PubMed. Analysis of the Prognosis of High-Grade gliomas in the View of New Immunohistochemistry Markers and 2016 WHO Classification
MGMT Promoter Methylation
MGMT is a DNA repair enzyme. When the gene’s promoter region is methylated (chemically silenced), the tumor has a harder time repairing the damage inflicted by temozolomide, the main chemotherapy drug used against high-grade gliomas. In the landmark 2005 trial, patients whose tumors had a methylated MGMT promoter and who received temozolomide plus radiation had a median survival of about 21.7 months, compared with 15.3 months for similar patients who received radiation alone. Without that methylation, the survival difference between treatment groups was small and not statistically meaningful.4PubMed. MGMT gene silencing and benefit from temozolomide in glioblastoma
The degree of methylation also appears to matter. A regional cohort study found that among patients who did not complete the full temozolomide regimen, higher MGMT methylation still predicted better survival, suggesting that even partial treatment can be more effective when the tumor’s repair mechanism is well suppressed.5PubMed Central. Extent of MGMT promoter methylation modifies the effect of temozolomide on overall survival in patients with glioblastoma: a regional cohort study The method used to test for methylation also influences the result’s reliability. Quantitative testing approaches appear to discriminate more sharply between methylated and unmethylated tumors in predicting both time to recurrence and overall survival.6PubMed Central. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response
How These Tumors Announce Themselves
High-grade gliomas do not always arrive with a dramatic event. Symptoms depend on where the tumor is growing and how quickly. A large Danish registry study found that focal neurological deficits — weakness on one side, speech difficulty, vision changes — were the most frequent presenting symptom overall. But seizures, which are more commonly the first sign of low-grade gliomas, can also be the initial symptom in high-grade cases. Headache as the only symptom at presentation turned out to be relatively rare. Older age, focal deficits, cognitive changes lasting less than three months, and new headache lasting less than a month all independently pointed toward a high-grade diagnosis.7PubMed. Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry
In practice, many patients describe a period of subtle personality or cognitive changes noticed by family members before more obvious neurological symptoms prompt medical imaging. By the time a high-grade glioma is found on MRI, it has typically been growing for some time.
Standard Treatment and What It Achieves
The backbone of treatment for high-grade glioma has been roughly the same since 2005: maximum safe surgical resection, followed by radiation with concurrent temozolomide, and then cycles of temozolomide alone. The trial that established this protocol, led by Roger Stupp, showed a median survival of 14.6 months with combined treatment versus 12.1 months with radiation alone. The two-year survival rate jumped from about 10% with radiation alone to roughly 27% with the addition of temozolomide.8PubMed. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Surgery’s contribution extends beyond just obtaining tissue for diagnosis. A meta-analysis found that removing as much tumor as safely possible (gross total resection) reduced the risk of death at one year by about 38% compared to partial removal, and partial removal itself was better than biopsy alone.9PubMed Central. Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis The challenge is that high-grade gliomas are diffuse, threading microscopic tendrils into normal brain tissue that the surgeon cannot see or safely remove. This is why recurrence is essentially universal.
Why High-Grade Gliomas Are So Difficult to Treat
Several biological features conspire to make these tumors among the hardest cancers to control. Each feature alone would be a serious obstacle; together, they create something close to a treatment-proof environment.
The blood-brain barrier is one fundamental problem. This tightly sealed layer of cells protects the brain from toxins in the bloodstream, but it also prevents most drugs from reaching tumor cells that have infiltrated beyond the main tumor mass. Even after surgery removes the visible tumor, scattered cells remain shielded from chemotherapy.10PubMed. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial
Glioma stem cells are another. These are a subset of tumor cells that sit in a dormant, slow-dividing state, which makes them resistant to both radiation and chemotherapy — treatments that primarily kill actively dividing cells. When treatment eliminates the bulk of the tumor, these stem cells survive and eventually regenerate it.11PubMed Central. The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence Their quiescent state and robust resistance mechanisms make them a primary driver of the nearly inevitable recurrence that defines glioblastoma.12PubMed. Hunting glioblastoma recurrence: glioma stem cells as retrospective targets
The tumor also actively suppresses the immune system in its vicinity. Gliomas recruit regulatory immune cells that dampen anti-tumor responses, reprogram nearby immune cells to adopt a tumor-supporting role, and release molecules that disable attacking T cells and natural killer cells.13PubMed Central. Immune suppression in gliomas This creates a microenvironment where the immune system not only fails to fight the tumor but is co-opted to support it.
Perhaps the most unsettling discovery of recent years is that glioma cells form functional connections with neurons. Rather than being passive lumps of abnormal tissue, these tumors integrate into neural circuits, forming real electrochemical synapses that allow them to hijack neuronal signaling to fuel their own growth and invasion. They extend long cytoplasmic tubes called tumor microtubules that connect glioma cells to each other and to neurons, creating a network that also helps the tumor resist treatment.14PubMed Central. Neuron-Glioma Synapses in Tumor Progression
Newer and Emerging Treatments
The past decade has seen several treatment approaches move from experimental curiosity to clinical use or advanced trials.
Tumor Treating Fields
Tumor treating fields (TTFields) use a portable device worn on the scalp that delivers low-intensity alternating electric fields to the brain. These fields interfere with the ability of dividing cells to properly separate their chromosomes, selectively disrupting rapidly dividing tumor cells while largely sparing normal tissue. Two major trials demonstrated that TTFields used alongside temozolomide improved both time before the tumor grew back and overall survival without causing the severe side effects associated with additional chemotherapy or radiation.15PubMed Central. Biophysical and Biological Mechanisms of Tumor Treating Fields in Glioblastoma The main downside is practical rather than medical: the device needs to be worn for at least 18 hours a day, and the arrays on the scalp are visible, which affects some patients’ willingness to use it consistently.
CAR-T Cell Therapy
Engineered immune cells (CAR-T cells) have transformed the treatment of certain blood cancers, and researchers are working to extend that success to brain tumors. A completed phase 1 trial evaluated CAR-T cells targeting a protein called IL-13Rα2, delivered directly into the brain, in 65 patients with recurrent high-grade glioma, most of whom had recurrent glioblastoma.16Nature Medicine. Locoregional delivery of IL-13Rα2-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial The trial focused on establishing safety and dosing. CAR-T therapy for brain tumors faces unique challenges, including the immunosuppressive tumor microenvironment described above and the difficulty of getting enough engineered cells past the blood-brain barrier, which is why direct injection into the brain or its fluid spaces is the delivery method being explored.
Targeted Molecular Therapies
A small percentage of gliomas carry a BRAF V600E mutation, the same mutation targeted by drugs already approved for melanoma. Early evidence suggests that BRAF inhibitors can produce prolonged disease control in gliomas harboring this mutation, and routine testing for BRAF status is increasingly recommended.17PubMed Central. Implications of BRAF V600E mutation in gliomas: Molecular considerations, prognostic value and treatment evolution However, gliomas can develop resistance by activating alternative growth pathways. Laboratory work has shown that combining BRAF inhibition with blockade of the EGFR pathway can prevent this escape mechanism, extending survival in animal models.18PubMed Central. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy
Focused Ultrasound for Drug Delivery
One approach to the blood-brain barrier problem uses focused ultrasound combined with tiny gas-filled microbubbles injected into the bloodstream. When ultrasound waves hit the microbubbles, they oscillate and temporarily loosen the tight junctions of the barrier, allowing chemotherapy to pass through into the brain tissue where infiltrating tumor cells hide. A phase 1/2 trial tested this technique with temozolomide in patients with high-grade glioma, aiming to deliver higher drug concentrations to the tumor bed than oral temozolomide alone can achieve.19PubMed. Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): a multicentre, open-label, phase 1/2 trial
The Pseudoprogression Problem
After finishing radiation and temozolomide, many patients undergo an MRI that looks worse, with increased enhancement suggesting the tumor is growing. In a substantial proportion of cases, this is pseudoprogression — treatment-related inflammation and tissue changes that mimic tumor growth on standard imaging. Distinguishing real progression from this treatment artifact matters enormously, because misreading pseudoprogression as failure can lead to premature changes in therapy or unnecessary surgery.
Standard MRI sequences cannot reliably make this distinction. Advanced techniques like dynamic contrast-enhanced MRI, which tracks how contrast agent moves through tissue over time, show promise. Studies have found that certain measurements of blood vessel permeability can help separate true tumor growth from inflammation.20PubMed Central. Dynamic Contrast-enhanced MRI Processing Comparison for Distinguishing True Progression From Pseudoprogression in High-grade Glioma Other approaches, including diffusion imaging and spectroscopy, are being evaluated for the same purpose, though no single technique has become the definitive standard.21PubMed Central. Metabolic and physiologic magnetic resonance imaging in distinguishing true progression from pseudoprogression in patients with glioblastoma In practice, neuro-oncologists often rely on a combination of imaging patterns, clinical symptoms, and time since treatment to make the call, sometimes opting for watchful waiting over immediate intervention.
Pediatric High-Grade Gliomas Are a Different Disease
High-grade gliomas in children are biologically distinct from those in adults, which is why the 2021 WHO classification separates them. The most devastating pediatric form is diffuse midline glioma, H3K27-altered, which includes tumors of the brainstem formerly called DIPG (diffuse intrinsic pontine glioma). More than 85% of DIPG tumors carry a specific mutation in genes encoding histone H3 proteins, leading to widespread disruption of gene regulation that drives tumor growth during critical periods of brain development.22PubMed Central. Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges
Because these tumors grow in the brainstem or other midline structures, surgery is rarely possible. Radiation provides temporary symptom relief but does not change the long-term outcome. Median survival for children with diffuse midline glioma remains under a year, making it one of the most lethal cancers in pediatric medicine. The molecular understanding of the H3K27M mutation has opened research into targeted approaches, but none has yet translated into a meaningfully improved survival in clinical trials.
Liquid Biopsies and Monitoring Without Surgery
Tracking a brain tumor’s molecular changes over time traditionally requires repeat surgery or biopsy, neither of which is trivial. Liquid biopsy — detecting tumor DNA fragments in body fluids — is being developed as a less invasive alternative. For brain tumors, cerebrospinal fluid (the fluid surrounding the brain and spinal cord) appears to be a far richer source of tumor DNA than blood, because the blood-brain barrier limits how much tumor DNA reaches the general circulation. Studies have shown that tumor-specific genetic changes can be detected in cerebrospinal fluid using sensitive sequencing techniques, potentially allowing doctors to monitor whether a tumor has recurred or evolved new mutations without another operation.23PubMed Central. Liquid Biopsy for Glioma Using Cell-Free DNA in Cerebrospinal Fluid The approach is still in its research phase, but it addresses a real clinical need: gliomas frequently change their molecular profile at recurrence, and catching those changes early could guide treatment decisions.
How Surgery Has Evolved Over a Century
The history of glioblastoma surgery puts the current state of care into useful perspective. The earliest reported craniotomy for glioblastoma resulted in the patient dying within a month. In the first major surgical series, published in 1912, mean survival was about ten months. Early postoperative death rates ran as high as 50% before improvements in managing brain swelling brought that figure down dramatically — Harvey Cushing’s series reduced surgical mortality to 6%.24PubMed. Historical Perspective on Surgery and Survival with Glioblastoma: How Far Have We Come? Survival did not budge from that roughly ten-month baseline until radiotherapy arrived in the 1950s, which doubled survival compared to surgery alone. The next major leap came only in 2005 with the addition of temozolomide. Decades of incremental neurosurgical improvements — frameless navigation, intraoperative imaging, awake craniotomy for tumors near critical brain regions — have made surgery safer and more complete, though the fundamental biological challenge of diffuse infiltration remains.25PubMed Central. Cutting Through History: The Evolution of Glioblastoma Surgery
Living with a High-Grade Glioma Diagnosis
The burden of high-grade glioma extends well beyond the tumor itself. These tumors can cause progressive cognitive decline, personality changes, fatigue, seizures, and loss of independence — sometimes all at once, and often worsening in ways that are difficult to predict. Patients and their families experience high levels of distress across physical, emotional, and cognitive dimensions, all compressed into a limited life expectancy.26PubMed Central. Palliative Care in High-Grade Glioma: A Review
Palliative care, which focuses on managing symptoms and supporting quality of life, is increasingly recommended alongside active treatment rather than only at the end of life. For older patients especially, where aggressive therapy carries higher risks, integrating palliative support from diagnosis onward can meaningfully improve day-to-day functioning and emotional well-being.27PubMed. The Evolving Role of Palliative Care in Older People with Glioblastoma
The Toll on Caregivers
The nature of brain tumors places unusual demands on family caregivers. Cognitive and behavioral changes can mean the patient becomes unable to participate in their own care decisions relatively early in the disease course, shifting an enormous weight onto a spouse, parent, or adult child. Research has documented that family caregivers of brain tumor patients provide extraordinary amounts of uncompensated care, often involving tasks they feel untrained for, across months or years that reshape their entire lives. Because the medical focus stays on the patient, caregivers’ own physical and mental health needs frequently go unaddressed.28Neuro-Oncology. Caring for the brain tumor patient: Family caregiver burden and unmet needs A systematic review confirmed that informal caregivers of glioma patients experience substantial rates of anxiety, depression, and general psychological distress, often at levels comparable to the patients themselves.29Asia-Pacific Journal of Oncology Nursing. Caregiver burden, quality of life, and psychosocial outcomes among informal caregivers of patients with glioma: A systematic review and meta-analysis
Support groups, respite care, and early involvement of social workers and palliative care teams can help, but access varies widely. The gap between what caregivers need and what the healthcare system provides remains one of the under-discussed aspects of high-grade glioma.